Artivion Announces Presentation of Real World Data from Post Market Study of On-X Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin
October 06, 2023 at 09:11 am EDT
Share
ATLANTA - Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its On-X Aortic Heart Valve Low INR post-market study presented in a Late-Breaking Science session at the 37th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Vienna, Austria.
Real world interim results for all patients confirm that the On-X Aortic Valve remains safe and effective with low-dose warfarin.
Professor Aung Oo, Clinical Lead for Aortovascular Surgery at Barts Heart Centre, London, England, presented an abstract titled, Real World Experience of 510 On-X Aortic Valve Replacement Patients Treated with Low Dose Warfarin. The abstract included at least 1-year and up to 5 years of clinical data on study participants, with median follow up time of 3.4 years. Results show a significantly lower composite primary endpoint of thromboembolism, valve thrombosis, and major bleeding (linearized occurrence rate (LOR) of 2.31% compared to the pre-defined historic control rate of 5.39%, p
Artivion, Inc. is a medical device company engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease, heart valve disease, aortic aneurysms, and dissections. The Company's segments include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, and On-X. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include BioGlue Surgical Adhesive products. It also sells or distributes PhotoFix bovine surgical patches.
Artivion Announces Presentation of Real World Data from Post Market Study of On-X Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin